NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326

CompletedPhase 2

Sponsor: Actelion

Conditions: Multiple Sclerosis

Interventions: Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg

Countries: United States, Austria, Bulgaria, Canada, Czechia, Finland, France, Germany

This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients who completed study treatment at their regular Week 24 (End of treatment) visit within the core study AC-058B201.
2. Signed informed consent for participating in the extension study.

Exclusion Criteria:

1\. Any clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the patient at risk by participating in the extension study.

Locations (71)

Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Palo Alto, California, United States
Sacramento, California, United States
Venice, Florida, United States
Indianapolis, Indiana, United States
Kansas City, Kansas, United States
Lenexa, Kansas, United States
Latham, New York, United States
Schenectady, New York, United States
Stony Brook, New York, United States
Raleigh, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Burlington, Vermont, United States
Kirkland, Washington, United States
Vienna, Austria
Sofia, Bulgaria
Ottawa, Ontario, Canada
Brno, Czechia
Jihlava, Czechia
Olomouc, Czechia
Ostrava-Poruba, Czechia
Prague, Czechia
Teplice, Czechia
Helsinki, Finland
Hyvinkää, Finland
Tampere, Finland
Turku, Finland
Montpellier, France
+ 41 more on CT.gov